Many US patients opt for obesity drug injections, defying some expectations

Medicare launched an 18‑month pilot letting people 65+ get GLP‑1 weight‑loss drugs (Wegovy, Foundayo, Zepbound) for $50/month, and demand is high.
Many seniors are choosing injectables over the new pills because injectables have shown larger weight loss in trials (as much as ~22% vs ~11–14% for pills).
Early rollout is mixed: most authorizations are rapid, but some patients face delays and clinicians report significant administrative hassle.